Not medical advice. I am a software engineer, not a physician. This page documents my own protocol and the research I read while building it. Talk to a qualified clinician before changing your supplementation, diet or any treatment. Lab reference ranges quoted here vary by laboratory and by individual.
Affiliate disclosure: the iHerb links on this page carry a referral code and pay me a commission if you buy. It does not change your price, and I do not link anything I do not use myself.
The eyes are the most metabolically active tissue per gram in the body. The retina has the highest oxygen consumption rate of any tissue, making it exceptionally vulnerable to oxidative damage. Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries, affecting 1 in 10 adults over 50. Diabetic retinopathy, driven by chronic hyperglycemia, is the leading cause of blindness in working-age adults. Both conditions are strongly influenced by nutritional status and systemic metabolic health.
Vision protection requires addressing three key areas: (1) macular pigment density (lutein, zeaxanthin, astaxanthin), which filters damaging blue light and UV radiation, (2) retinal structural integrity (DHA, vitamin A), which maintains photoreceptor function, and (3) systemic metabolic health (blood sugar control, inflammation management), which prevents microvascular damage to the retina.
DHA is the retina's structural foundation: DHA (docosahexaenoic acid) comprises 60% of the fatty acids in retinal photoreceptor membranes. It is essential for the visual signaling cascade (rhodopsin function). Low Omega-3 Index (<4%) is associated with a 2-fold increased risk of AMD. Unlike most tissues, the retina cannot synthesize DHA locally — it depends entirely on dietary/supplement intake.
The retina contains two types of photoreceptors (rods for low-light vision, cones for color and detail) that convert light into electrical signals. The macula, at the retina's center, provides sharp central vision and is especially rich in the carotenoids lutein and zeaxanthin, which serve as natural blue-light filters and antioxidants.
Age-Related Eye Disease Study 2 Research Group (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration (AREDS2). JAMA, 309(19), 2005-2015. PubMed 23644932
These supplements target the three pillars of eye health: macular pigment density, retinal structural integrity, and antioxidant protection against UV and blue light damage.
| Supplement | Role | Timing | Details |
|---|---|---|---|
| Vitamin A (Retinol) | Essential for rhodopsin synthesis; prevents night blindness and corneal degeneration | 5000-10000 IU/day with fat-containing meals | Vitamin A |
| Omega-3 DHA | Primary structural fatty acid of photoreceptor membranes; maintains membrane fluidity for visual signaling | 1-2 g DHA/day with meals | Omega-3 |
| Astaxanthin | Carotenoid antioxidant 6000x stronger than vitamin C; crosses blood-retinal barrier; reduces eye fatigue from screens; UV protection | 4-12 mg/day with fat | Astaxanthin |
| Zinc (Picolinate) | Cofactor for retinol dehydrogenase (visual cycle); stabilizes rhodopsin; AREDS-proven for AMD prevention | 15-25 mg/day with meals | Zinc Picolinate |
Astaxanthin for the digital age: A 2012 clinical trial found that 6 mg/day of astaxanthin significantly reduced eye strain, dryness, and blurred vision in office workers spending 6+ hours/day on screens. Its unique ability to span cell membranes provides dual protection — quenching free radicals both inside and outside photoreceptor cells. It also improves retinal capillary blood flow, supporting nutrient delivery to the macula.
While comprehensive eye exams are irreplaceable, blood tests can reveal systemic risk factors that drive the most common causes of vision loss.
| Test | What It Measures | Frequency | Details |
|---|---|---|---|
| Vitamin A (Retinol) | Essential for rhodopsin and visual cycle; deficiency causes night blindness and xerophthalmia | Every 12 months | Lab Tests |
| Vitamin D (25-OH) | Vitamin D receptors in retinal pigment epithelium; deficiency associated with increased AMD risk | Every 6 months | Lab Tests |
| HbA1c | Average blood sugar over 2-3 months; each 1% reduction lowers diabetic retinopathy progression risk by 35-40% | Every 6-12 months | Lab Tests |
| Omega-3 Index | EPA+DHA as % of RBC membranes; optimal >8% for retinal protection; low index doubles AMD risk | Every 12 months | Lab Tests |
Diabetes is the silent eye destroyer: Diabetic retinopathy begins with microaneurysms in retinal capillaries, progresses to hemorrhages and exudates, and can culminate in retinal detachment and blindness. It develops silently — patients often have no symptoms until significant damage has occurred. Every diabetic and prediabetic individual should have annual dilated eye exams. HbA1c <6.0% is the most protective target for retinal health.
Lutein meta-analysis confirms dose-response for macular protection. A 2025 meta-analysis established that lutein supplementation at 10-20 mg/day significantly increases macular pigment optical density (MPOD), visual acuity, and contrast sensitivity, with larger improvements at 20 mg/day and treatment durations beyond 6 months. For digital eye strain, a 2025 clinical study found that 10 mg lutein + 2 mg zeaxanthin improved tear test results and photo-stress recovery time in participants using screens over 6 hours daily. Researchers now believe circularly-oriented macular pigment levels could serve as an early screening tool for age-related macular degeneration (AMD), enabling intervention before irreversible damage occurs.
Nano-cubosome eyedrops deliver lutein to the retina without injections. Researchers at RMIT and the Centre for Eye Research Australia developed a nano-carrier formula that delivers lutein directly to retinal tissue via eyedrops, avoiding the need for invasive intravitreal injections. In mouse models, the formulation reached the back of the eye and remained shelf-stable at room temperature for months. Separately, gene therapy for geographic atrophy (dry AMD) advanced significantly: Ocugen reported in January 2026 that OCU-410 slowed the growth of atrophic lesions by 46%, representing a potential paradigm shift from managing symptoms to treating the underlying disease.